Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: CXCR4 PET/CT Imaging.
- Who it may be relevant to
- Registry conditions: CXCR4-related Disease, Tumor, Positron Emission Tomography, Metastasis. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Detailed description
Subjects with various CXCR4-related disease patients underwent 68Ga/18F-Pentixafor/Pentixather PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Pentixafor/Pentixather PET/CT were calculated.
Interventions
- Diagnostic test CXCR4 PET/CT Imaging
Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Primary outcome measures
- Standardized uptake value (SUV) [Time frame: 30 days]
Secondary outcome measures (1)
- Diagnostic efficacy [Time frame: 30 days]
Eligibility criteria
Inclusion criteria
- suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
- 18F-FDG PET/CT within two weeks
- signed written consent.
Exclusion criteria
- pregnancy
- breastfeeding
- known allergy against Pentixafor
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Tianjin Medical University General Hospital — Tianjin
Identifiers
NCT: NCT06690736 · TJMUGH-02